Charles Schwab Investment Management Inc. Sells 3,780 Shares of Bicara Therapeutics Inc. $BCAX

Charles Schwab Investment Management Inc. reduced its stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) by 2.4% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 153,004 shares of the company’s stock after selling 3,780 shares during the period. Charles Schwab Investment Management Inc. owned about 0.28% of Bicara Therapeutics worth $1,994,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of the stock. Red Tree Management LLC bought a new position in shares of Bicara Therapeutics during the fourth quarter valued at about $55,230,000. Deep Track Capital LP increased its stake in Bicara Therapeutics by 151.0% in the 4th quarter. Deep Track Capital LP now owns 2,000,000 shares of the company’s stock valued at $34,840,000 after buying an additional 1,203,148 shares during the last quarter. Braidwell LP lifted its position in shares of Bicara Therapeutics by 20.7% during the 4th quarter. Braidwell LP now owns 2,000,659 shares of the company’s stock worth $34,851,000 after buying an additional 343,059 shares in the last quarter. Vestal Point Capital LP boosted its stake in shares of Bicara Therapeutics by 67.1% in the 4th quarter. Vestal Point Capital LP now owns 710,000 shares of the company’s stock worth $12,368,000 after buying an additional 285,000 shares during the last quarter. Finally, Blackstone Inc. boosted its stake in shares of Bicara Therapeutics by 40.5% in the 4th quarter. Blackstone Inc. now owns 913,060 shares of the company’s stock worth $15,906,000 after buying an additional 263,060 shares during the last quarter.

Wall Street Analysts Forecast Growth

BCAX has been the subject of a number of research analyst reports. Wells Fargo & Company raised Bicara Therapeutics from an “underweight” rating to an “equal weight” rating and set a $8.00 price target for the company in a research report on Friday, May 23rd. Wedbush reaffirmed an “outperform” rating and set a $30.00 target price on shares of Bicara Therapeutics in a research report on Tuesday, August 12th. HC Wainwright cut their price target on shares of Bicara Therapeutics from $41.00 to $40.00 and set a “buy” rating on the stock in a report on Friday, August 22nd. Piper Sandler assumed coverage on shares of Bicara Therapeutics in a research report on Monday, August 18th. They set an “overweight” rating and a $36.00 price target for the company. Finally, Wall Street Zen lowered shares of Bicara Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, Bicara Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $32.25.

Bicara Therapeutics Stock Performance

Shares of BCAX opened at $11.94 on Monday. Bicara Therapeutics Inc. has a fifty-two week low of $7.80 and a fifty-two week high of $28.09. The business has a 50-day moving average of $10.64 and a 200 day moving average of $11.87. The firm has a market cap of $651.45 million and a P/E ratio of -3.77.

Bicara Therapeutics (NASDAQ:BCAX) last issued its earnings results on Tuesday, August 12th. The company reported ($0.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.04. As a group, research analysts predict that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.